Cargando…

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

OBJECTIVE: To investigate glial and neuronal biomarkers in cerebrospinal fluid (CSF) samples from patients with relapsing–remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS), and to evaluate their ability to predict conversion from CIS to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez, M Alba Mañé, Olsson, Bob, Bau, Laura, Matas, Elisabet, Calvo, Álvaro Cobo, Andreasson, Ulf, Blennow, Kaj, Romero-Pinel, Lucia, Martínez-Yélamos, Sergio, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390605/ https://www.ncbi.nlm.nih.gov/pubmed/25732842 http://dx.doi.org/10.1177/1352458514549397

Ejemplares similares

Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients
por: Matas, Elisabet, et al.
Publicado: (2014)

Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
por: Romero-Pinel, Lucía, et al.
Publicado: (2022)

Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series
por: Cobo Calvo, Álvaro, et al.
Publicado: (2013)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
por: Rosén, Christoffer, et al.
Publicado: (2014)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
por: Johansson, Per, et al.
Publicado: (2017)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke
por: Hjalmarsson, Clara, et al.
Publicado: (2014)

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
por: Minta, Karolina, et al.
Publicado: (2020)

Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis
por: Mens, Helene, et al.
Publicado: (2022)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

The Relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and Synaptic Biomarkers (Ng, NPTXR) in Early Alzheimer’s Disease
por: Kulczyńska-Przybik, Agnieszka, et al.
Publicado: (2023)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Kappa free light chains index in multiple sclerosis very long-term prognosis
por: Arroyo-Pereiro, Pablo, et al.
Publicado: (2023)

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System
por: Mattsson, Niklas, et al.
Publicado: (2012)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2rjb0dgdqpjpt2e51qohv9c8pp